{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:09:14Z","timestamp":1789495754114,"version":"build-2803163510"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>People with haemophilia A (PwHA) experience acute and chronic pain associated with reduced quality of life (QoL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>This post hoc analysis of pooled data from the HAVEN 1 (NCT02622321), 3 (NCT02847637), 4 (NCT03020160) and STASEY (NCT0319179) studies assessed the impact of emicizumab prophylaxis on pain\u2010related QoL in PwHA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PwHA received emicizumab during the four studies. In this analysis, pain was assessed using patient\u2010reported responses to pain\u2010specific questions from the Haem\u2010A\u2010QoL\/Haemo\u2010QoL\u2010SF and the pain\/discomfort dimension of the EQ\u20105D\u20105L. Responses were recorded at baseline and at regular intervals for up to 78 weeks following treatment initiation. Additional analyses evaluated the population with target joints at baseline, and the overall population stratified by age, factor (F)VIII inhibitor status and prior treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At the data cut\u2010off, 504 PwHA had been treated across the four studies; 464 and 470 completed the Haem\u2010A\u2010QoL\/Haemo\u2010QoL\u2010SF and the EQ\u20105D\u20105L, respectively. Improvements in pain\u2010related QoL were observed by Week 13 of emicizumab prophylaxis and maintained through Week 78. In the overall population, responses of \u2018never\/rarely\u2019 for \u2018my swellings hurt\u2019 and \u2018pain in joints\u2019 increased from 37.0% and 30.0% at baseline to 84.0% and 61.0% by Week 13, suggesting reductions in acute and chronic pain, respectively. Similar improvements were seen in the target joint population, and across all strata. Greater improvements were observed in younger versus older PwHA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Pain\u2010related QoL improved with emicizumab prophylaxis regardless of target joints, age, FVIII inhibitor status or prior treatment. Haemophilia\u2010specific assessments are needed to accurately capture and characterize pain in PwHA.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.15134","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T13:29:55Z","timestamp":1734528595000},"page":"87-98","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pain\u2010Related Quality of Life Outcomes in People With Haemophilia A Receiving Emicizumab: A Post Hoc Analysis of the HAVEN 1, 3 and 4 and STASEY Studies"],"prefix":"10.1111","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-8437","authenticated-orcid":false,"given":"Cedric","family":"Hermans","sequence":"first","affiliation":[{"name":"Haemostasis and Thrombosis Unit, Division of Haematology Cliniques Universitaires Saint\u2010Luc Catholic University of Louvain (UCLouvain)  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0934-0680","authenticated-orcid":false,"given":"Mark W.","family":"Skinner","sequence":"additional","affiliation":[{"name":"Department of Health Research Methods, Evidence and Impact McMaster University  Hamilton Ontario Canada"},{"name":"Institute for Policy Advancement Ltd  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Gentile","sequence":"additional","affiliation":[{"name":"Product Development Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Lim","sequence":"additional","affiliation":[{"name":"Data &amp; Statistical Sciences OMNI Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Minhas","sequence":"additional","affiliation":[{"name":"US Medical Affairs Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Moreno","sequence":"additional","affiliation":[{"name":"Global Product Development\/Medical Affairs (PDMAO) F. Hoffmann\u2010La Roche Ltd  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Tzeng","sequence":"additional","affiliation":[{"name":"Rare Blood Disease, US Medical Affairs Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1954-4385","authenticated-orcid":false,"given":"Tyler W.","family":"Buckner","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Colorado School of Medicine  Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-020-01798-4"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13763"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13214"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14105"},{"issue":"1","key":"e_1_2_11_7_1","first-page":"78","article-title":"Physical Activity in Persons With Hemophilia (PwH) From France (FR), Italy (ITA), and United States (US) From the Hemactive Patient Survey","volume":"25","author":"Nugent D.","year":"2019","journal-title":"Haemophilia"},{"issue":"1","key":"e_1_2_11_8_1","first-page":"137","article-title":"Part\u2010Time Employment and Early Retirement in People With Severe Haemophilia: Insights From the PROBE Study","volume":"25","author":"Skinner M. W.","year":"2019","journal-title":"Haemophilia"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.2478\/jhp-2021-0020"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13025"},{"key":"e_1_2_11_11_1","unstructured":"Food and Drug Administration.HEMLIBRA\u00ae (emicizumab\u2010kxwh) Injection for Subcutaneous Use Prescribing Information [Initial U.S. Approval: 2017](Silver Spring MD:Food and Drug Administration 2022) accessed November 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761083s015lbl.pdf#page=22."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH17-01-0030"},{"key":"e_1_2_11_13_1","unstructured":"Emicizumab Global Medical Information Site(Basel Switzerland:Roche 2023) accessed November 2024 https:\/\/www.emicizumabinfo.global\/en\/homepage\/faq.html."},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703068"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001869"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12670"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00377-5"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12837"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S63265"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221079482"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.2214.2214"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1355-0691.2004.00875.x"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01292.x"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12672"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009217"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14261"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194303"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14318"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28942"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2021.2004269"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14363"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14183"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13618"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-528414"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14642"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001311"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"issue":"1","key":"e_1_2_11_41_1","first-page":"121","article-title":"Impact on Pain and Activities of Daily Living After Switching to Emicizumab: Insights From PROBE","volume":"29","author":"Kucher A.","year":"2023","journal-title":"Haemophilia"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.15134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T05:22:14Z","timestamp":1738214534000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.15134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1111\/hae.15134"],"URL":"https:\/\/doi.org\/10.1111\/hae.15134","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"2024-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}